CLINICAL EFFICACY OF INJECTABLE CLINDAMYC IN

Many owners of dogs and cats with periodontal diseases have difficulty with the peroral application of clindamycin in capsules. Injectable c lindamycin phosphate was given subcutaneously at a dose of 11 mg/kg bo dyweight once daily for 5 days and the level of plaque and gingivitis in 10 dogs with chronic oral inflammatory disease was measured before and at the. end of treatment. There was an 86 per cent reduction in ae robic and anaerobic bacteria as measured by UV-fluorescence photograph y and plaque-planimetry which was statistically significant (p = 0,000 01). There was an 80 per cent reduction in the gingivitis index which was also statistically significant (p = 0,00001). No pain was detected at the time of injection and the only minor side effect observed was slightly soft feces in some dogs. Injectable clindamycin phosphate app ears to be a valuable alternative treatment regime for non-cooperative dogs with periodontal disease.